Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | MGAM | O43451 | 1/20 | 0.36 |
| ▸ | SI | P14410 | 1/20 | 0.36 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.33 |
| ▸ | LMNA | P02545 | 3/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | MITF | O75030 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | CASP3 | P42574 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.31 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.31 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.31 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3189044 | 0.89 | MAPT (0.40) | MAPTGAAMGAMSIMGAM2 | |
| SCHEMBL4671913 | 0.86 | MAPT (0.42) | MAPTGAAMGAMSIMGAM2 | |
| SCHEMBL7011293 | 0.80 | GAA (0.42) | MAPTGAAMGAMSIMGAM2 | |
| SCHEMBL7811246 | 0.80 | MAPT (0.34) | MAPTGAAMGAMSIMGAM2 | |
| SCHEMBL9049112 | 0.79 | ALDH1A1 (0.38) | MAPTGAAMGAMSIMGAM2 | |
| SCHEMBL5704377 | 0.78 | GAA (0.47) | MAPTGAAMGAMSIMGAM2 | |
| SCHEMBL7009937 | 0.78 | ALDH1A1 (0.40) | MAPTGAAMGAMSIMGAM2 | |
| SCHEMBL7173265 | 0.77 | MAPT (0.34) | MAPTALDH1A1LMNAPOLBKDM4E | |
| SCHEMBL7011507 | 0.76 | MAPT (0.38) | MAPTGAAALDH1A1LMNAMAPK1 | |
| SCHEMBL19728721 | 0.76 | GAA (0.38) | MAPTGAAMGAMSIMGAM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190276407-A1 | NOVEL PYRIDONECARBOXYLIC ACID DERIVATIVE OR SALT THEREOF | WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) | 2019-09-12 | — | — | US | disclosed |
| EP-3473616-A1 | NOVEL PYRIDONECARBOXYLIC ACID DERIVATIVE OR SALT THEREOF | Wakunaga Pharmaceutical Co., Ltd. (JP) | 2019-04-24 | — | — | EP | disclosed |
| EP-0787720-B1 | PYRIDONECARBOXYLATE DERIVATIVE OR SALT THEREOF AND ANTIBACTERIAL CONTAINING THE SAME AS ACTIVE INGREDIENT | WAKUNAGA SEIYAKU KK (JP) | 2003-07-16 | — | — | EP | disclosed |
| EP-0952151-B1 | Intermediates for use in preparing novel pyridonecarboxylic acid derivatives or their salts | WAKUNAGA PHARMA CO LTD (JP) | 2003-05-28 | — | — | EP | disclosed |
| EP-0911327-B1 | NOVEL PYRIDONECARBOXYLIC ACID DERIVATIVES OR THEIR SALTS AND ANTIBACTERIAL AGENT COMPRISING THE SAME AS THE ACTIVE INGREDIENT | WAKUNAGA PHARMA CO LTD (JP) | 2001-12-05 | — | — | EP | disclosed |
| US-6156903-A | Pyridonecarboxylic acid derivatives or their salts, and antibacterial agents containing the same as their effective components | WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) | 2000-12-05 | — | — | US | disclosed |
| US-6133284-A | EXCELLENT BACTERICIDAL PROPERTIES AND ORAL ABSORPTION; INFECTIONS FROM GRAMNEGATIVE AND -POSITIVE BACTERIA; INTESTINAL ABSORPTION, METABOLIC STABILITY; SIDE EFFECT REDUCTION; NONPHOTOTOXICITY AND NONCYTOTOXICITY | WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) | 2000-10-17 | — | — | US | disclosed |
| EP-0992501-A2 | Pyridonecarboxylic acid derivatives as antibacterial agents | WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) | 2000-04-12 | — | — | EP | disclosed |
| US-5998436-A | Pyridonecarboxylic acid derivatives or their salts and antibacterial agent comprising the same as the active ingredient | WAKUNAGA PHARMACEUTICALS CO., LTD. (JP) | 1999-12-07 | — | — | US | disclosed |
| EP-0952151-A2 | Intermediates for use in preparing novel pyridonecarboxylic acid derivatives or their salts | WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) | 1999-10-27 | — | — | EP | disclosed |
| US-5910498-A | NOVEL COMPOUNDS HAVING REDUCED CYTOTOXICITY, PHOTOTOXICITY; TREATING BACTERIAL AND VIRAL INFECTIONS | WAKUNAGA SEIYAKU KABUSHIKI KAISHA (JP) | 1999-06-08 | — | — | US | disclosed |
| EP-0911327-A1 | NOVEL PYRIDONECARBOXYLIC ACID DERIVATIVES OR THEIR SALTS AND ANTIBACTERIAL AGENT COMPRISING THE SAME AS THE ACTIVE INGREDIENT | WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) | 1999-04-28 | — | — | EP | disclosed |
| EP-0787720-A1 | NOVEL PYRIDONECARBOXYLATE DERIVATIVE OR SALT THEREOF AND ANTIBACTERIAL CONTAINING THE SAME AS ACTIVE INGREDIENT | WAKUNAGA SEIYAKU KABUSHIKI KAISHA (JP) | 1997-08-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190276407-A1 | NOVEL PYRIDONECARBOXYLIC ACID DERIVATIVE OR SALT THEREOF | CTR9, PYCR1, ACAD9 | MAPT 4806/4885GAA 4830/4885MGAM 3764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.